Apostolski 1998.

Methods	Double‐blind, placebo controlled study
Participants	Country: Yugoslavia Single centre Diagnosis: ALS, World Federation of Neurology Participants: 35 (14 treated with antioxidant, 7 placebo, 7 nimodipine, 7 amino acids. 60% male) Age: mean 54 years Inclusion criteria not stated Exclusion criteria ‐ family history of neurological disease Side effects ‐ none
Interventions	1. Alsamin ‐ selenium, vitamin E, b‐carotene, L‐arginine, L‐leucine, L‐isoleucine, L‐valine, L‐methionine, nimodipine 2. selenium, vitamin E, b‐carotene 3. L‐arginine, L‐methionine, L‐leucine, L‐isoleucine, L‐valine 4. nimodipine 5. placebo
Outcomes	Primary: Erythrocyte enzyme activity of Copper zinc superoxide dismutase, glutathione peroxidase, catalase, glutathione reductase, and plasma activity of glutathione transferase Secondary: Change in Norris score
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: not addressed
Allocation concealment (selection bias)	Unclear risk	Comment: not addressed
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"double blind" Comment: not addressed further
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: not addressed
Selective reporting (reporting bias)	Unclear risk	Comment: insufficient information
Other bias	Unclear risk	Comment: insufficient information